Skip to Main Content

Paper Details

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.
Cancer Chemother Pharmacol
8
2021
Author NameAffiliation
Charles Patrick ReynoldsCancer Center, Texas Tech University Health Sciences Center
  • 1 - 1

Datasets

Release 1.2